HUE054973T2 - Szilíciumdioxid-nanorészecskék és alkalmazásuk oltásnál - Google Patents

Szilíciumdioxid-nanorészecskék és alkalmazásuk oltásnál

Info

Publication number
HUE054973T2
HUE054973T2 HUE17175233A HUE17175233A HUE054973T2 HU E054973 T2 HUE054973 T2 HU E054973T2 HU E17175233 A HUE17175233 A HU E17175233A HU E17175233 A HUE17175233 A HU E17175233A HU E054973 T2 HUE054973 T2 HU E054973T2
Authority
HU
Hungary
Prior art keywords
vaccination
silicon dioxide
dioxide nanoparticles
nanoparticles
silicon
Prior art date
Application number
HUE17175233A
Other languages
English (en)
Inventor
Markus Weigandt
Andrea Hanefeld
Armin Kuebelbeck
Gregor Larbig
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUE054973T2 publication Critical patent/HUE054973T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
HUE17175233A 2008-07-15 2009-07-13 Szilíciumdioxid-nanorészecskék és alkalmazásuk oltásnál HUE054973T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008033175A DE102008033175A1 (de) 2008-07-15 2008-07-15 Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung

Publications (1)

Publication Number Publication Date
HUE054973T2 true HUE054973T2 (hu) 2021-10-28

Family

ID=41165124

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09777154A HUE036309T2 (hu) 2008-07-15 2009-07-13 Szilícium-dioxid nanoszemcsék és ezek alkalmazása vakcináláshoz
HUE17175233A HUE054973T2 (hu) 2008-07-15 2009-07-13 Szilíciumdioxid-nanorészecskék és alkalmazásuk oltásnál

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE09777154A HUE036309T2 (hu) 2008-07-15 2009-07-13 Szilícium-dioxid nanoszemcsék és ezek alkalmazása vakcináláshoz

Country Status (17)

Country Link
US (4) US8980324B2 (hu)
EP (2) EP2299980B1 (hu)
JP (3) JP5726075B2 (hu)
KR (2) KR101694130B1 (hu)
CN (2) CN102099014B (hu)
AU (1) AU2009270468B2 (hu)
BR (2) BRPI0915788B8 (hu)
CA (1) CA2730694C (hu)
DE (1) DE102008033175A1 (hu)
DK (2) DK2299980T3 (hu)
EA (1) EA023047B1 (hu)
ES (2) ES2640012T3 (hu)
HU (2) HUE036309T2 (hu)
MX (1) MX341881B (hu)
PT (2) PT2299980T (hu)
WO (1) WO2010006753A2 (hu)
ZA (1) ZA201101171B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791827B (zh) 2009-11-09 2016-11-16 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
AU2011317142B2 (en) 2010-10-18 2015-04-23 University of Washington Center for Commercialization Chromophoric polymer dots
US9028880B2 (en) * 2010-11-30 2015-05-12 The Board Of Trustees Of The University Of Illinois Silica nanoparticle agent conjugates
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
CN103012594B (zh) * 2011-09-22 2015-09-02 中国农业科学院兰州兽医研究所 一种运载猪圆环病毒抗原表位蛋白的纳米载体及应用
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
EP2797635B1 (en) 2011-12-30 2020-05-20 University of Washington Through Its Center for Commercialization Chromophoric polymer dots with narrow-band emission
WO2013116614A1 (en) 2012-02-03 2013-08-08 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
EP2644703A1 (en) * 2012-03-26 2013-10-02 ETH Zurich Molecular code system
GB201205237D0 (en) * 2012-03-26 2012-05-09 Univ Edinburgh Adjuvant
BR112015017966A2 (pt) * 2013-01-31 2017-07-11 Univ Portland State composições imunogênicas compreendendo vírus silificado e métodos de uso
CN103175661B (zh) * 2013-03-01 2015-06-24 南京理工大学 一种微纳米生产粉尘泄露源的同位素法定位检测方法
JP6587605B2 (ja) 2013-03-14 2019-10-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション ポリマードット組成物および関連方法
EP3220913B1 (en) * 2014-11-19 2021-09-08 Kiromic BioPharma, Inc. Nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies
JP6868862B2 (ja) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
CN105597094A (zh) * 2015-12-31 2016-05-25 河南农业大学 猪传染性胃肠炎病毒纳米硅佐剂灭活疫苗及其制备方法
EP3405432A1 (en) * 2016-01-25 2018-11-28 King Abdullah University Of Science And Technology Methods of making silica nanoparticles, propellants, and safety devices
ES2879881T3 (es) 2016-08-10 2021-11-23 Res & Innovation Uk Composiciones que comprenden partículas de nanosílice y su uso en métodos de activación de linfocitos T para terapia
US20200246441A1 (en) * 2016-08-19 2020-08-06 Amrita Vishwa Vidyapeetham Compositions and methods for autoimmune disease treatment
DE102017116370A1 (de) * 2017-07-20 2019-01-24 Leibniz-Institut Für Neue Materialien Gemeinnützige Gmbh Siliziumdioxidnanopartikel zur therapeutischen Anwendung
US10952904B2 (en) * 2017-11-28 2021-03-23 International Business Machines Corporation Antimicrobial bandage with nanostructures
WO2019152672A1 (en) * 2018-01-31 2019-08-08 Prolynx Llc Aseptic method and apparatus to prepare sterile formulations of drug-linked hydrogel microspheres
KR102166606B1 (ko) * 2018-10-12 2020-10-16 한국교통대학교산학협력단 대식세포 표적형 나노어셈블리 및 이를 포함하는 항염증 조성물
AU2020377966A1 (en) * 2019-11-04 2022-05-19 Cornell University Ultrasmall nanoparticles and methods of making, using and analyzing same
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN111973741B (zh) * 2020-08-23 2023-01-10 中国医学科学院生物医学工程研究所 pH响应型基于共包载抗原和光敏剂的介孔硅纳米粒的治疗性疫苗的制备方法
CN112641935B (zh) * 2020-10-15 2023-05-23 百葵锐(深圳)生物科技有限公司 一种含颗粒载体的亚单位疫苗及其应用
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114081961B (zh) * 2021-11-10 2024-02-23 中国科学技术大学 复合纳米颗粒、制备方法、应用
CN114377120B (zh) * 2022-01-10 2023-09-22 大连理工大学 一种以病毒样颗粒为模板的二氧化硅疫苗递送系统的构建及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616133A1 (de) * 1985-09-25 1987-11-19 Merck Patent Gmbh Kugelfoermige sio(pfeil abwaerts)2(pfeil abwaerts)-partikel
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
IL109519A (en) * 1994-05-03 1999-03-12 Yeda Res & Dev Vaccines for oral immunization against infecting agents
US6086881A (en) 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
EP1202745A4 (en) 1999-08-16 2004-09-22 Henceforth Hibernia Inc THERAPEUTIC AND PROPHYLACTIC COMPOSITIONS CONTAINING CATALYTIC BIOMIMETIC SOLIDS AND METHODS OF PREPARING AND USING SAME
ATE320267T1 (de) * 2000-08-11 2006-04-15 Lohmann Animal Health Gmbh W/o emulsion adjuvanszuzammensetzungen für impstoffen
ES2304467T3 (es) * 2001-07-10 2008-10-16 North Carolina State University Vehiculo de liberacion de nanoparticulas.
JP2004138522A (ja) * 2002-10-18 2004-05-13 Meneki Seibutsu Kenkyusho:Kk 腫瘍診断剤およびその用途
US20040202720A1 (en) 2003-04-10 2004-10-14 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
DE102004011110A1 (de) 2004-03-08 2005-09-22 Merck Patent Gmbh Verfahren zur Herstellung monodisperser SiO2-Partikel
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
JP2009501237A (ja) 2005-03-14 2009-01-15 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生物活性ｆｕｓ１ペプチドおよびナノ粒子−ポリペプチド複合体
JP4735954B2 (ja) * 2005-06-03 2011-07-27 独立行政法人産業技術総合研究所 抗体産生キャリア
DE102005033954A1 (de) * 2005-07-20 2007-01-25 Switzerland c/o Laris Fiduciara Sca, Ethios Zusammensetzung, die eine liposomale Dispersion von SiO2-Nanopartikeln und ein ß-1,3-verknüpftes Glucanetherderivat umfasst
CA2621352A1 (en) * 2005-09-08 2007-03-15 Biterials Co., Ltd. Magnetic nanoparticle having fluorescent and preparation method thereof and use thereof
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US8603530B2 (en) * 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US20080171059A1 (en) 2006-08-07 2008-07-17 Shanshan Wu Howland Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
WO2008109366A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
WO2008109852A2 (en) * 2007-03-07 2008-09-12 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
CN100567145C (zh) * 2007-07-19 2009-12-09 东华大学 单分散磁性二氧化硅纳米颗粒的制备方法
CA2746124A1 (en) * 2008-12-11 2010-06-17 The Governors Of The University Of Alberta Methods and systems for inducing immunologic tolerance to non-self antigens

Also Published As

Publication number Publication date
JP2015042694A (ja) 2015-03-05
US20110123620A1 (en) 2011-05-26
EP3241545B1 (de) 2021-04-28
KR20110039351A (ko) 2011-04-15
EP3241545A2 (de) 2017-11-08
EA023047B1 (ru) 2016-04-29
MX2011000401A (es) 2011-03-15
DK3241545T3 (da) 2021-07-12
KR101694130B1 (ko) 2017-01-09
DE102008033175A1 (de) 2010-01-21
AU2009270468B2 (en) 2014-08-21
BRPI0915788B1 (pt) 2020-10-20
EP2299980B1 (de) 2017-06-14
AU2009270468A1 (en) 2010-01-21
ES2885055T3 (es) 2021-12-13
ES2640012T3 (es) 2017-10-31
US8980324B2 (en) 2015-03-17
CN102099014B (zh) 2015-08-26
BR122019011790B8 (pt) 2021-07-27
JP2011527996A (ja) 2011-11-10
KR20170005169A (ko) 2017-01-11
CA2730694A1 (en) 2010-01-21
US9808521B2 (en) 2017-11-07
JP6109805B2 (ja) 2017-04-05
DK2299980T3 (en) 2017-09-11
JP2017031222A (ja) 2017-02-09
ZA201101171B (en) 2011-10-26
JP6479744B2 (ja) 2019-03-06
EP2299980A2 (de) 2011-03-30
CN105126115A (zh) 2015-12-09
US9433673B2 (en) 2016-09-06
BRPI0915788B8 (pt) 2021-05-25
WO2010006753A2 (de) 2010-01-21
EP3241545A3 (de) 2017-12-13
US10111952B2 (en) 2018-10-30
MX341881B (es) 2016-09-07
PT3241545T (pt) 2021-07-30
CN105126115B (zh) 2020-11-27
WO2010006753A3 (de) 2010-04-29
PT2299980T (pt) 2017-09-19
BRPI0915788A2 (pt) 2015-11-10
US20150224189A1 (en) 2015-08-13
JP5726075B2 (ja) 2015-05-27
CN102099014A (zh) 2011-06-15
CA2730694C (en) 2017-10-10
US20180071386A1 (en) 2018-03-15
US20160303228A1 (en) 2016-10-20
KR101973841B1 (ko) 2019-04-29
EA201100190A1 (ru) 2011-08-30
BR122019011790B1 (pt) 2020-12-15
HUE036309T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
ZA201101171B (en) Silicon dioxide nanoparticles and their use for vaccination
IL215389A0 (en) Pneumococcal vaccine and uses thereof
ZA201008045B (en) Nanoparticle formulations and uses thereof
IL215665A0 (en) Nanoparticle formulations and uses therof
IL207802A0 (en) Hollow nanoparticles and uses thereof
IL208698A0 (en) Photonic mixer and use thereof
EP2451741A4 (en) SEMICONDUCTOR ANOKRISTAL AND MANUFACTURING METHOD THEREFOR
EP2341798A4 (en) INFANT CARE DEVICE
IL215765A0 (en) Prion-free nanoparticle compositions and methods
EP2449102A4 (en) ARGINASE FORMULATIONS AND METHODS
EP2268673A4 (en) POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF
PL2448724T3 (pl) Aparat do higieny osobistej
HK1144787A1 (en) Anti-fmd vaccine composition and preparation and use thereof
EP2498732A4 (en) HIP TRACTION DEVICE AND METHODS
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
ZA201003680B (en) Oral care methods and systems
EP2378912A4 (en) PERSONAL TRAINER
PL2285450T3 (pl) Kompozycje do higieny jamy ustnej i sposoby
GB0823497D0 (en) Immunogenic composition and use thereof
ZA201103645B (en) Single-time vaccines
GB0920125D0 (en) Delivery device and delivery methods
IL212118A0 (en) Anthrax vaccine formulation and uses thereof
ZA201204530B (en) Oral care compositions and methods
EP2453916A4 (en) SUPRALINGUAL VACCINES AND SUPRALINGUAL APPLICATORS
HK1173995A1 (en) Use of ferroquine in the treatment of malaria